Martin Edwards - 18 Jun 2024 Form 4 Insider Report for Inozyme Pharma, Inc. (INZY)

Reporting relationship: Director
Issuer ticker: INZY
Reported as of: 18 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Jun 2024, 16:07:25 UTC
Prior SEC filing: 05 Jun 2024
Next SEC filing: 21 Aug 2024
Source filing: View source filing
Reporting owner signature: /s/ Sanjay Subramanian, as attorney-in-fact for Martin Edwards

Key filing fact

Martin Edwards filed Form 4 for Inozyme Pharma, Inc. (INZY) on 20 Jun 2024.

Key facts

This page summarizes Martin Edwards's Form 4 filing for Inozyme Pharma, Inc. (INZY).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 Jun 2024, 16:07.

Change

Previous filing in this sequence was filed on 05 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INZY transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +28,000
Change %
Price: $0.000000
Shares after: 28,000
Date: 18 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 28,000
Exercise price: $4.40
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option was granted on June 18, 2024. The shares underlying the option are scheduled to vest as to 100% of the shares on June 18, 2025, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date.